Allergy Conjunctivitis Global Market Report 2025

Allergic conjunctivitis is the inflammation of the conjunctiva, the membrane covering the inside of eyelids and the white part of the eyeball. This inflammation is triggered by an allergic reaction to substances like pollen or mold spores. Symptoms of allergic conjunctivitis include red, itchy, and watery eyes.

The main drug classes used for treating allergic conjunctivitis are antihistamines and mast cell stabilizers, corticosteroids, and others. Antihistamines and mast cell stabilizers are medications, available either by prescription or over-the-counter, that work to inhibit the physiological action of histamines. The severity of the disease can range from mild to severe, and medications for conjunctivitis are distributed through various channels, including hospital pharmacies, drug stores, retail pharmacies, and online pharmacies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The allergy conjunctivitis market research report is one of a series of new reports from The Business Research Company that provides allergy conjunctivitis market statistics, including allergy conjunctivitis industry global market size, regional shares, competitors with allergy conjunctivitis market share, detailed allergy conjunctivitis market segments, market trends, and opportunities, and any further data you may need to thrive in the allergy conjunctivitis industry. This allergy conjunctivitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The allergy conjunctivitis market size has grown steadily in recent years. It will grow from $2.51 billion in 2024 to $2.63 billion in 2025 at a compound annual growth rate (CAGR) of 4.6%. The growth in the historic period can be attributed to increasing incidence of allergic conditions, advancements in research and development, changing lifestyles and environmental factors, expansion of patient awareness, collaborations and partnerships, healthcare infrastructure development.

The allergy conjunctivitis market size is expected to see strong growth in the next few years. It will grow to $3.31 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to increasing global allergy burden, personalized medicine approaches, growing geriatric population, biotechnological innovations, expanding healthcare access in developing regions, regulatory support and approvals. Major trends in the forecast period include integration of novel drug delivery technologies, emphasis on patient education and awareness, development of combination therapies, incorporation of artificial intelligence (ai) in diagnosis, rise in environmental allergen management solutions.

The forecast of 5.9% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. ophthalmology practices by inflating prices of ocular antihistamines and mast cell stabilizers manufactured in Italy and Belgium, resulting in delayed eye allergy relief and higher vision care costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing exposure to air pollutants and chemicals is projected to drive growth in the allergy conjunctivitis market in the coming years. Human eyes, being one of the most sensitive parts of the body, are continually at risk due to persistent exposure to harmful substances present in air pollution. Prolonged exposure to airborne pollutants and chemicals can lead to various eye problems, including allergic conjunctivitis, burning sensations, watering, blurred vision, redness, itching, and chronic discomfort, necessitating treatments. For example, in April 2022, the World Health Organization, a Switzerland-based international public health agency, reported that nearly the entire global population (99%) is exposed to air that exceeds the organization's air quality standards, posing significant health risks. Over 6,000 cities across 117 countries are now monitoring air quality, yet residents in these areas continue to inhale unhealthy levels of fine particulate matter and nitrogen dioxide, with individuals in low and middle-income countries facing the highest exposure levels. Thus, the rise in exposure to air pollutants and chemicals is fueling the growth of the allergy conjunctivitis market.

The prevalence of eye disorders is another key driver propelling the growth of the allergy conjunctivitis market. Eye disorders encompass various conditions affecting eye structure or function, resulting in impaired vision or related symptoms. Allergic conjunctivitis stands as a substantial contributor to these eye disorders, particularly when triggered by allergic reactions to environmental elements like pollen, dust, or pet dander. The surge in environmental pollutants and chemicals has led to an uptick in cases of allergic conjunctivitis. Globally, over 2.2 billion people are affected by near or distance vision impairment, with various conditions like cataracts, refractive errors, age-related macular degeneration, glaucoma, and diabetic retinopathy, as per the World Health Organization's report. This prevalence of eye disorders contributes significantly to the growth of the allergy conjunctivitis market.

Product innovation emerges as a pivotal trend driving the allergy conjunctivitis market. Key companies in this sector are intensifying their focus on developing innovative and advanced products to bolster their market presence. For instance, Allergan, an Irish-US-based medical company, introduced LASTACAFT, an eye allergy drop in March 2022. This brand of eye drops delivers relief from itchiness and allergies within three minutes and offers sustained relief for up to 16 hours. LASTACAFT, an antihistamine eye drop, targets histamines triggering ocular itching, effectively calming allergic responses caused by pollen, ragweed, grass, animal hair, and dander in individuals aged two and above. The launch of such innovative solutions expands the company's retail eye drop portfolio, ensuring quality eye care products for consumers.

Major companies in the allergy conjunctivitis market are actively pursuing strategic partnerships to fortify their market presence. These business collaborations involve structured affiliations between two or more enterprises, typically established through formal business agreements or contracts. For instance, in May 2022, AffaMed Therapeutics, a China-based biopharmaceutical company, entered into a partnership with Primal Chemical. This collaboration aims to enhance AffaMed's capabilities, enabling healthcare institutions and practitioners to offer patients more treatment options, including IOLs and DEXTENZA, specifically for patients in Hong Kong and Macau. Primal Chemical, based in Hong Kong, specializes in chemical solutions.

In July 2023, Harrow Health, a prominent U.S.-based company focused on the ophthalmic healthcare market, made an acquisition of the branded ophthalmic portfolio from Santen Holdings U.S. Inc. This strategic acquisition empowers Harrow Health to solidify its position as a leading player among top-tier U.S. ophthalmic pharmaceutical companies. The addition of Santen's branded portfolio significantly enriches Harrow Health's offerings, establishing it as one of the most comprehensive portfolios available in the U.S. market. Santen Holdings U.S. Inc. operates as a U.S.-based provider of ophthalmology solutions and is dedicated to human eye health.

Major companies operating in the allergy conjunctivitis market are Allergan PLC, AbbVie Inc., Ajanta Pharma Limited, Akron Operating Company LLC, Alcon Inc., Alembic Pharmaceuticals Ltd., Atopix Therapeutics Ltd., Auven Therapeutics Management LLLP, Bausch & Lomb, Cipla Ltd., Grevis Pharmaceutical Private Limited, Indoco Remedies Ltd., Jabs Biotech Pvt. Ltd., JAWA Pharmaceuticals Pvt. Ltd., Novartis AG, Ocular Therapeutix Inc., Santen Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Laboratoires Thea SAS, Aciex Therapeutics Inc., Bausch Health Companies Inc., C.H. Boehringer Sohn AG & Co. KG, Eyevance Pharmaceuticals LLC, Johnson & Johnson Services Inc., Mylan N.V., Nicox S.A., Omeros Corporation, Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Shire PLC, Teva Pharmaceutical Industries Ltd., Zydus Cadila

North America was the largest region in the allergy conjunctivitis market share in 2024. The regions covered in the allergy conjunctivitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the allergy conjunctivitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The allergy conjunctivitis market consists of sales of therapeutics that are used to treat inflammation of eyes caused due to allergens. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Allergy Conjunctivitis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on allergy conjunctivitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for allergy conjunctivitis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The allergy conjunctivitis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Antihistamines And Mast Cell Stabilizers; Corticosteroids; Other Drug Classes
• 2) By Disease Type: Mild; Severe
• 3) By Distribution Channel: Hospital Pharmacies; Drug Stores And Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Antihistamines And Mast Cell Stabilizers: Topical Antihistamines; Oral Antihistamines; Mast Cell Stabilizers
• 2) By Corticosteroids: Topical Corticosteroids; Systemic Corticosteroids
• 3) By Other Drug Classes: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs); Combination Therapy; Immunotherapy; Leukotriene Receptor Antagonists
• Companies Mentioned: Allergan PLC; AbbVie Inc.; Ajanta Pharma Limited; Akron Operating Company LLC; Alcon Inc.; Alembic Pharmaceuticals Ltd.; Atopix Therapeutics Ltd.; Auven Therapeutics Management LLLP; Bausch & Lomb; Cipla Ltd.; Grevis Pharmaceutical Private Limited; Indoco Remedies Ltd.; Jabs Biotech Pvt. Ltd.; JAWA Pharmaceuticals Pvt. Ltd.; Novartis AG; Ocular Therapeutix Inc.; Santen Pharmaceutical Co. Ltd.; Sun Pharmaceutical Industries Ltd.; Laboratoires Thea SAS; Aciex Therapeutics Inc.; Bausch Health Companies Inc.; C.H. Boehringer Sohn AG & Co. KG; Eyevance Pharmaceuticals LLC; Johnson & Johnson Services Inc.; Mylan N.V.; Nicox S.A.; Omeros Corporation; Otsuka Pharmaceutical Co. Ltd.; Pfizer Inc.; Regeneron Pharmaceuticals Inc.; Shire PLC; Teva Pharmaceutical Industries Ltd.; Zydus Cadila
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.